Alaunos Therapeutics (TCRT) Shares Outstanding (Diluted Average) (2009 - 2026)

Alaunos Therapeutics has reported Shares Outstanding (Diluted Average) for 15 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 21.68% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 21.68% YoY), and the FY2025 full-year result was $1.9 million, up 21.68% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $1.9 million, roughly flat from $1.9 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $215.1 million in Q3 2022, with the low at $1.6 million in Q2 2023.
• Historically, Shares Outstanding (Diluted Average) has averaged $40.9 million across 5 years, with a median of $1.6 million in 2025.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Diluted Average) plunged 99.26% — and 2025, when it climbed 21.68%.
• Alaunos Therapeutics' Shares Outstanding (Diluted Average) stood at $14.5 million in 2022, then sank by 88.95% to $1.6 million in 2023, then climbed by 0.11% to $1.6 million in 2024, then increased by 21.68% to $1.9 million in 2025, then changed by 0.0% to $1.9 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.